1. Home
  2. SNDX vs KRO Comparison

SNDX vs KRO Comparison

Compare SNDX & KRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • KRO
  • Stock Information
  • Founded
  • SNDX 2005
  • KRO 1916
  • Country
  • SNDX United States
  • KRO United States
  • Employees
  • SNDX N/A
  • KRO N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • KRO Major Chemicals
  • Sector
  • SNDX Health Care
  • KRO Industrials
  • Exchange
  • SNDX Nasdaq
  • KRO Nasdaq
  • Market Cap
  • SNDX 974.9M
  • KRO 803.0M
  • IPO Year
  • SNDX 2016
  • KRO N/A
  • Fundamental
  • Price
  • SNDX $11.54
  • KRO $6.88
  • Analyst Decision
  • SNDX Strong Buy
  • KRO Hold
  • Analyst Count
  • SNDX 10
  • KRO 3
  • Target Price
  • SNDX $36.20
  • KRO $12.00
  • AVG Volume (30 Days)
  • SNDX 1.9M
  • KRO 246.3K
  • Earning Date
  • SNDX 05-07-2025
  • KRO 05-07-2025
  • Dividend Yield
  • SNDX N/A
  • KRO 2.91%
  • EPS Growth
  • SNDX N/A
  • KRO N/A
  • EPS
  • SNDX N/A
  • KRO 0.75
  • Revenue
  • SNDX $23,680,000.00
  • KRO $1,887,100,000.00
  • Revenue This Year
  • SNDX $286.51
  • KRO $13.24
  • Revenue Next Year
  • SNDX $120.86
  • KRO $7.35
  • P/E Ratio
  • SNDX N/A
  • KRO $9.18
  • Revenue Growth
  • SNDX N/A
  • KRO 13.24
  • 52 Week Low
  • SNDX $9.66
  • KRO $6.19
  • 52 Week High
  • SNDX $25.07
  • KRO $14.50
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 44.37
  • KRO 41.36
  • Support Level
  • SNDX $9.66
  • KRO $6.67
  • Resistance Level
  • SNDX $11.61
  • KRO $7.22
  • Average True Range (ATR)
  • SNDX 1.01
  • KRO 0.41
  • MACD
  • SNDX 0.02
  • KRO 0.04
  • Stochastic Oscillator
  • SNDX 56.12
  • KRO 47.92

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About KRO Kronos Worldwide Inc

Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The majority of revenue comes from the United States.

Share on Social Networks: